Stay updated with breaking news from Eric Swayze. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective raised by Oppenheimer from $65.00 to $72.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an outperform rating on the stock. Several other research analysts have also recently weighed in on IONS. Bank of America raised Ionis Pharmaceuticals from a neutral […]
Swiss National Bank raised its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 283,100 shares of the company’s stock after purchasing an additional 3,000 […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Eric Swayze sold 10,773 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $52.00, for a total transaction of $560,196.00. Following the transaction, the executive vice president now owns 32,516 shares in the company, valued […]
Operator: Good morning, and welcome to Ionis' Third Quarter 2023 Financial Results Conference Call. As a reminder this call is being recorded. At this time, I would like to turn the call over Mr.
The deal allows the companies to leverage data from Scipher's Spectra platform and identify subgroups of patients most likely to benefit from treatment.